We are a contract research organization targeting the $150Bn antibody therapeutics market. We have developed a patented, cutting-edge technology that is customer-ready today. Our differentiated technology is better than existing solutions and has been developed with customer feedback from the beginning. Our service-driven business model has limited capital needs, 70% operating margins and multiple customers ready to work with us right now.